Bye-Bayer

29 Mar 2022 By Ed Cropley

Four years on, the 61 bln euro group’s Monsanto purchase has left it with cancer litigation and a clunky structure. Its current worth may be 32% less than the value of its bits, arguing for a breakup. That’s hard while boss Werner Baumann, the deal’s architect, is in place.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)